Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Allogeneic CD19 CAR T cells demonstrated promising overall and durable CR rates with a manageable safety profile in CD19 CAR T-naïve patients with R/R LBCL, supporting additional evaluation of cema-cel in patients with LBCL.
Authors
- Mehdi Hamadani (ORCID: https://orcid.org/0000-0001-5372-510X)
- Geoffrey Shouse (ORCID: https://orcid.org/0000-0002-7917-5713)
- Frederick Lundry Locke (ORCID: https://orcid.org/0000-0001-9063-6691)
- John B. Le Gall (ORCID: https://orcid.org/0000-0002-6558-6108)
- Don A. Stevens
- Olalekan O. Oluwole (ORCID: https://orcid.org/0000-0001-8525-9641)
- Lynn Navale
- Michael Tees
- Sattva Swarup Neelapu (ORCID: https://orcid.org/0000-0003-1045-4914)
- Lazaros J. Lekakis (ORCID: https://orcid.org/0009-0008-2077-7032)
- Sven de Vos (ORCID: https://orcid.org/0000-0002-6715-4851)
- David B. Miklos (ORCID: https://orcid.org/0000-0003-0717-4305)
- Miguel‐Angel Perales (ORCID: https://orcid.org/0000-0002-5910-4571)
- Javier Muñoz (ORCID: https://orcid.org/0000-0002-9060-8911)
- Shahbaz A. Malik (ORCID: https://orcid.org/0000-0001-9435-3285)
- Rajneesh Nath
- P.W. Fisher (ORCID: https://orcid.org/0000-0003-4153-1935)
- Amy Feng
Institutions
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Norton Healthcare (US)
- Medical College of Wisconsin (US)
- Moffitt Cancer Center (US)
- Sarah Cannon (US)
- University of Miami Health System (US)
- Allogene Therapeutics (United States) (US)
- St David's Medical Center (US)
- Mayo Clinic Hospital (US)
- Colorado Blood Cancer Institute (US)
- Sylvester Comprehensive Cancer Center (US)
- Vanderbilt University Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1200/jco-24-01933
- Citations
- 27
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 28.23